Meeting
2019 ASCO Annual Meeting
Retrospective analysis of overall survival (OS) by subsequent therapy in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) receiving irinotecan ± cetuximab in the EPIC study.
Authors
Alberto F. Sobrero
IRCCS Ospedale San Martino IST, Genova, Italy
Alberto F. Sobrero , Heinz-Josef Lenz , Cathy Eng , Werner Scheithauer , Gary William Middleton , Wen-Feng Chen , Regina Esser , Johannes Nippgen , Howard A. Burris III
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3580)
DOI
10.1200/JCO.2019.37.15_suppl.3580
Abstract #
3580
Poster Bd #
72
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan—Biomarker analysis.
First Author: Yasushi Tsuji
Poster
2017 Gastrointestinal Cancers Symposium
Utilization of systemic therapy options in the routine treatment of metastatic colorectal cancer.
First Author: Rachel Lee Delahunty
Poster
2014 ASCO Annual Meeting
Randomized phase II study of regorafenib followed by cetuximab versus reverse sequence for wild-type KRAS metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and irinotecan (REVERCE).
First Author: Kohei Shitara
Poster
2012 Gastrointestinal Cancers Symposium
Panitumumab (Pmab) versus cetuximab (Cmab)/irinotecan (Iri) therapy among patients with KRAS wild-type (wt) metastatic colorectal cancer (MCRC).
First Author: Hagen F. Kennecke